Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Jul 22:6:19-21.
doi: 10.1016/j.gynor.2013.07.004. eCollection 2013.

A case of primary metastatic glassy cell carcinoma of the uterine cervix that responded to combined docetaxel and carboplatin

Yuji Ukita  1 , Hiroshi Tsubamoto  1 , Toru Kato  1 , Shigeo Suno  2 , Hiroaki Shibahara  1
Affiliations

A case of primary metastatic glassy cell carcinoma of the uterine cervix that responded to combined docetaxel and carboplatin

Yuji Ukita et al. Gynecol Oncol Case Rep. .

Abstract

•Glassy cell carcinoma (GCC) of the cervix is rare and aggressive.•A few case reports have described a response to intravenous chemotherapy for this malignancy.•This is the first report of a GCC case that responded to a combination of docetaxel and carboplatin.

Keywords: Carboplatin; Cervical cancer; Chemotherapy; Docetaxel; Glassy cell carcinoma.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Histological diagnosis of glassy cell carcinoma (magnification: A, 40 ×; B, 400 ×).
Fig. 2
Fig. 2
A coronal 18F-fluorodeoxyglucose (FDG)-positron emission tomography scan showing significant FDG uptake in the (A) retroperitoneal and supraclavicular lymph nodes, (B) paraaortic lymph nodes, and (C) pelvic lymph node.
Fig. 3
Fig. 3
Radiological and serological response during chemotherapy consisting of docetaxel and carboplatin (DC). The duration of the response and the progression free survival were 73 days and 128 days, respectively. The radiological response was evaluated according to the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. The sum of the diameters in the short axis of the left paraaortic and right external iliac lymph nodes is shown.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Hirashima Y., Kobayashi H., Nishiguchi T., Miura K., Kanayama N. A case of glassy cell carcinoma of the uterine cervix effectively responding to chemotherapy with paclitaxel and carboplatin. Anticancer Drugs. 2001;12:627–630. - PubMed
    1. Kitagawa R., Katsumata N., Shibata T., Nakanishi T., Nishimura S., Ushijima U. A randomized, phase III trial of paclitaxel plus carboplatin (TC) versus paclitaxel plus cisplatin (TP) in stage IVb, persistent or recurrent cervical cancer: Japan Clinical Oncology Group study (JCOG0505) J. Clin. Oncol. 2012;30 (Suppl.; abstr 5006) - PubMed
    1. Kitagawa R., Katsumata N., Ando M., Shimizu C., Fujiwara Y., Yoshikawa H. A multi-institutional phase II trial of paclitaxel and carboplatin in the treatment of advanced or recurrent cervical cancer. Gynecol. Oncol. 2012;125:307–311. - PubMed
    1. Matsuura Y., Murakami N., Nagashio E., Toki N., Kashimura M. Glassy cell carcinoma of the uterine cervix: combination chemotherapy with paclitaxel and carboplatin in recurrent tumor. J. Obstet. Gynaecol. Res. 2001;27:129–132. - PubMed
    1. Mikami M., Ezawa S., Sakaiya N., Komuro Y., Tei C., Fukuchi T., Mukai M. Response of glassy-cell carcinoma of the cervix to cisplatin, epirubicin, and mitomycin C. Lancet. 2000;355:1159–1160. - PubMed

LinkOut - more resources